15
Views
16
CrossRef citations to date
0
Altmetric
Research Article

Interleukin-12 and interleukin-18 change ICAM-I expression, and enhance natural killer cell mediated cytolysis of human osteosarcoma cells

, , , , , , & show all
Pages 135-142 | Published online: 26 Sep 2009

References

  • Rhim JS, Cho HY, Huebner RJ, Non-producer human cells induced by murine sarcoma virus. Int J Cancer (1975) 15: 23–9.
  • Fogh J, Fogh JM, Orfeo T, One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst (1977) 59: 221–6.
  • Billiau A, Edy VG, Heremans H et al, Human interferon: mass production in a newly established cell line, MG-63. Antimicrob Agents Chemother (1977) 12: 11–5.
  • Ponten J, Saksela E, Two established in vitro cell lines from human mesenchymal tumours. Int J Cancer (1967) 2: 434–47.
  • Scotlandi K, Baldini N, Campanacci M et al, Induction of HLA class II antigens in osteosarcoma cells by interferons and tumor necrosis factor alpha. Anticancer Res (1992) 12: 767–72.
  • Mariani E, Tarozzi A, Meneghetti A et al, Human osteosarcoma cell susceptibility to natural killer cell lysis depends on CD54 and increases after TNF alpha incubation. FEBS Lett (1997) 406: 83–8.
  • Lehmann C, Glass B, Zeis M et al, Investigating the lysis of smallcell lung cancer cell lines by activated natural killer (NK) cells with a fluorometric assay for NK-cell-mediated cytotoxicity. Cancer Immunol Immunother (1999) 48: 209–13.
  • Podack ER, Hengartner H, Lichtenheld MG, A central role of perforin in cytolysis? Annu Rev Immunol (1991) 9: 129–57.
  • Henkart PA, Lymphocyte-mediated cytotoxicity: two pathways and multiple effector molecules. Immunity (1994) 1: 343–6.
  • D’Andrea A, Rengaraju M, Valiante NM et al, Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J Exp Med (1992) 176: 1387–98.
  • Chan SH, Perussia B, Gupta JW et al, Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med (1991) 173: 869–79.
  • Kobayashi M, Fitz L, Ryan M et al, Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med (1989) 170: 827–45.
  • Ushio S, Namba M, Okura T et al, Cloning of the cDNA for human IFN-gamma-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein. J Immunol (1996) 156: 4274–9.
  • Micallef MJ, Ohtsuki T, Kohno K et al, Interferon-gamma-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon-gamma production. Eur J Immunol (1996) 26: 1647–51.
  • Lauwerys BR, Renauld JC, Houssiau FA, Synergistic proliferation and activation of natural killer cells by interleukin 12 and interleukin 18. Cytokine (1999) 11: 822–30.
  • Yoshimoto T, Takeda K, Tanaka T et al, IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-γ production. J Immunol (1998) 161: 3400–7.
  • Coughlin CM, Salhany KE, Wysocka M et al, Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest (1998) 101: 1441–52.
  • Yamanaka K, Hara I, Nagai H et al, Synergistic antitumor effects of interleukin-12 gene transfer and systemic administration of interleukin-18 in a mouse bladder cancer model. Cancer Immunol Immunother (1999) 48: 297–302.
  • Rodella L, Rezzani R, Zauli G et al, Apoptosis induced by NK cells is modulated by the NK-active cytokines IL-2 and IL-12. Int Immunol (1998) 10: 719–25.
  • Hogg N, Landis RC, Adhesion molecules in cell interactions. Curr Opin Immunol (1993) 5: 383–90.
  • Kohka H, Yoshino T, Iwagaki H et al, Interleukin-18/interferon-gamma-inducing factor, a novel cytokine, up-regulates ICAM-1 (CD54) expression in KG-1 cells. J Leukoc Biol (1998) 64: 519–27.
  • Brunda MJ, Luistro L, Hendrzak JA et al, Role of interferongamma in mediating the antitumor efficacy of interleukin-12. J Immunother Emphasis Tumor Immunol (1995) 17: 71–7.
  • Nastala CL, Edington HD, McKinney TG et al, Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol (1994) 153: 1697–706.
  • Zitvogel L, Tahara H, Robbins PD et al, Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. J Immunol (1995) 155: 1393–403.
  • Wigginton JM, Komschlies KL, Back TC et al, Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. J Natl Cancer Inst (1996) 88: 38–43.
  • Benacerraf B, Role of MHC gene products in immune regulation. Science (1981) 212: 1229–38.
  • Tanaka K, Yoshioka T, Bieberich C, Jay G, Role of the major histocompatibility complex class I antigens in tumor growth and metastasis. Annu Rev Immunol (1988) 6: 359–80.
  • Bernards HJ, Suppression of MHC gene expression in cancer cells. Trends Genetics (1987) 3: 298–301.
  • Bontkes HJ, Walboomers JM, Meijer CJ et al, Specific HLA class I down-regulation is an early event in cervical dysplasia associated with clinical progression. Lancet (1998) 351: 187–8.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.